|
Redx Pharma PLC - Cheshire-based cancer and fibrosis drug developer - Announces end of 2023 as start of phase 1 studies for its Crohn's disease clinical development candidate RXC008. The inhibitor is designed to act exclusively in the gastrointestinal tract at the site of fibrosis in Crohn's disease patients. Up to 50% of patients with Crohn's disease can develop significant fibrosis, the company says, citing a 2013 study published by the National Center for Biotechnology Information based in Bethesda, Maryland, United States.
‘Crohn's disease associated fibrosis is an area with high unmet need, with no treatment currently available except for invasive surgery,’ explains Chief Executive Officer Lisa Anson.
The company adds: ‘This programme will be the third development candidate that Redx has progressed in the area of fibrosis.’
Current stock price: 72.05 pence, down 0.6% on Wednesday
12-month change: down 0.6%
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
